Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
962 results about "CRISPR" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
CRISPR (/ˈkrɪspər/) (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found within the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that have previously infected the prokaryote and are used to detect and destroy DNA from similar phages during subsequent infections. Hence these sequences play a key role in the antiviral (i.e. anti-phage) defense system of prokaryotes.
Methods and Compositions for the Targeted Modification of a Genome
Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the LTVEC with a CRISPR / Cas system. Compositions and methods for generating a genetically modified non-human animal comprising one or more targeted genetic modifications in their germline are also provided.
Owner:REGENERON PHARM INC
PROKARYOTIC RNAi-LIKE SYSTEM AND METHODS OF USE
Provided herein are methods for inactivating a target polynucleotide. The methods use a psiRNA having a 5′ region and a 3′ region. The 5′ region includes, but is not limited to, 5 to 10 nucleotides chosen from a repeat from a CRISPR locus immediately upstream of a spacer. The 3′ region is substantially complementary to a portion of the target polynucleotide. The methods may be practiced in a prokaryotic microbe or in vitro. Also provided are polypeptides that have endonuclease activity in the presence of a psiRNA and a target polynucleotide, and methods for using the polypeptides.
Owner:UNIV OF GEORGIA RES FOUND INC
Crispr-based genome modification and regulation
InactiveUS20140273230A1Polypeptide with localisation/targeting motifHydrolasesGenomeDNA Endonuclease
Owner:SIGMA ALDRICH CO LLC
Crispr-based genome modification and regulation
Owner:SIGMA ALDRICH CO LLC
Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events
ActiveUS20160024529A1Eliminate generationMinimize the numberBacteriaHydrolasesIn vivoHost cell filopodium
The present invention provides a method for making a large nucleic acid having a defined sequence in vivo. The method combines recombineering techniques with a CRISPR / Cas system to permit multiple insertions of defined sequences into a target nucleic acid at one time, double stranded cleavage of target nucleic acids in which the defined sequences were not successfully inserted, and selection of successful recombinant cells. The method further includes repeating the process one or more times, using a successful recombinant from one round as the host cell for the next round.
Owner:AGILENT TECH INC
Methods Of Modifying A Sequence Using CRISPR
InactiveUS20160053272A1Effective positioningAccurate modificationFermentationVector-based foreign material introductionNucleic acid sequenceBioinformatics
Methods of modifying one or more target nucleic acid sequences using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR associated (Cas) proteins (CRISPR / Cas) system are disclosed. Methods of introducing one or more exogenous nucleic acid sequences into one or more circular nucleic acid sequences using the CRISPR / Cas system are also disclosed.
Owner:WHITEHEAD INST FOR BIOMEDICAL RES
Methods Of Depleting Target Sequences Using CRISPR
InactiveUS20160053304A1Microbiological testing/measurementLibrary creationNucleic acid sequencingBiology
Methods of depleting one or more target nucleic acid sequences using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR associated (Cas) proteins (CRISPR / Cas) system are disclosed. Kits and methods of producing a library comprising select mRNA sequences using the CRISPR / Cas system are also disclosed.
Owner:WHITEHEAD INST FOR BIOMEDICAL RES
Prokaryotic RNAi-like system and methods of use
Owner:UNIV OF GEORGIA RES FOUND INC
Method of adaptor-dimer subtraction using a crispr cas6 protein
A method of processing a target RNA is provided. In certain embodiments, this method comprises: contacting the products of an RNA ligase-mediated ligation reaction with an CAS6 protein, wherein: (i) the RNA ligase-mediated ligation reaction comprises: a target RNA, an RNA ligase, and first and second adaptors that can ligate together to produce an adaptor dimer that contains a CRISPR stem loop; and (ii) the CAS6 protein recognizes the CRISPR stem loop; thereby preventing the adaptor dimer from being reverse transcribed.
Owner:AGILENT TECH INC
Methods and compositions for the targeted modification of a genome
Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the LTVEC with a CRISPR / Cas system. Compositions and methods for generating a genetically modified non-human animal comprising one or more targeted genetic modifications in their germline are also provided.
Owner:REGENERON PHARM INC
Cultures with Improved Phage Resistance
InactiveUS20110002889A1Reduced degree of homologyReduce decreaseBiocideBacteriaVirulent characteristicsBacteriophage
The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, the present invention provides compositions and methods for the use of one or more cas genes or proteins for modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In additional embodiments, the present invention provides methods for labelling and / or identifying bacteria. In some preferred embodiments, the present invention provides methods for the use of CRISPR loci to determine the potential virulence of a phage against a cell and the use of CRISPR-cas to modulate the genetic sequence of a phage for increased virulence level. In still further embodiments, the present invention provides means and compositions for the development and use of phages as biocontrol agents.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Method for constructing gene site-directed mutation
ActiveCN103388006AEfficient constructionRaise the ratioVector-based foreign material introductionForeign genetic material cellsMulti siteEmbryo
Owner:BIORAY LABORATORIES INC
Crispr-based genome modification and regulation
Owner:SIGMA ALDRICH CO LLC
Methods and compositions for the production of guide RNA
Various aspects and embodiments of the present disclosure relate to methods and compositions that combine multiple mammalian RNA regulatory strategies, including RNA triple helix structures, introns, microRNAs, and ribozymes with Cas-based CRISPR transcription factors and ribonuclease-based RNA processing in human cells. The methods and compositions of the present disclosure, in some embodiments, enable multiplexed production of proteins and multiple guide RNAs from a single compact RNA-polymerase-II-expressed transcript for efficient modulation of synthetic constructs and endogenous human promoters.
Owner:MASSACHUSETTS INST OF TECH
Sequence specific antimicrobials
ActiveUS20160024510A1Reduce the amount requiredUnwanted amountOrganic active ingredientsBiocideBacteroidesMicrobial agent
Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and / or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
Owner:THE ROCKEFELLER UNIV
Crispr-based genome modification and regulation
Owner:SIGMA ALDRICH CO LLC
Improving sequence-specific antimicrobials by blocking DNA repair
The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.
Owner:INST PASTEUR +1
Methods and compositions for producing double allele knock outs
The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.
Owner:LARIX BIOSCI
Crispr-based genome modification and regulation
Owner:SIGMA ALDRICH CO LLC
Detection method of specific nucleic acid fragment based on CRISPR-Cas13a
InactiveCN107557455AEasy to operateHigh sensitivityMicrobiological testing/measurementRNA SequenceBiological materials
The invention relates to the detection of biological materials, and particularly discloses a rapid detection method based on CRISPR-Cas13a which is suitable for a specific nucleic acid fragment in a biological sample. A to-be-detected nucleic acid fragment is amplified to obtain a transcription product; a guide RNA (Ribonucleic Acid) is designed by aiming at a target RNA sequence of a target gene,and an RNA molecule is reported by a signal added in a detection system; the amplification and read of the signal are realized by using the RNA enzymatic activity of the Cas13a protein, which is activated after recognizing the target RNA sequence and is not limited by the sequence, further the detection of the target gene is realized. The detection sensitivity of the method provided by the invention can reach 10 to 18mol / L, namely ammol level, and the specificity can be achieved for detecting the nucleic acid fragments with single-base difference.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Preparation method for transgenic mice capable of producing human nerve growth factor
ActiveCN104561095AEasy to operateIncrease success rateAnimals/human peptidesVector-based foreign material introductionPlasmid dnaGenetically modified mouse
The invention discloses a method for producing transgenic mice through a homologous recombination technology. The method comprises the following steps: replacing mouse NGF genes on mouse chromosomes by human NGF genes through a Cas-9 / CRISPR gene knock-in technology, and obtaining the genes with homozygous human NGF genes through breeding and knocking the genes in mice, thus obtaining filial generation mice with salivary glands capable of secreting human NGF. Compared with the conventional targeting technology utilizing positive and negative double screening homologous recombination genes, the method disclosed by the invention is simple to operate, capable of being realized only by transfecting mouse embryonic stem cells by three plasmid DNAs or carrying out pronucleus injection on the zygotes of mice, and high in success rate which is up to 2-5% and remarkably higher than the mouse embryonic stem cell positive rate of 0.1% of the common gene targeting technology.
Owner:深圳市国创纳米抗体技术有限公司
Crispr-based genome modification and regulation
The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR / Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
Owner:SIGMA ALDRICH CO LLC
Method for specifically knocking out human CCR5 (Chemokine Receptor 5) gene by CRISPR (clustered regularly interspaced short palindromic repeat-associated)-Cas 9 and SgRNA (single guide RNA) for specifically targeting CCR5 gene
ActiveCN103923911AKnockout efficiency is lowImprove efficiencyVector-based foreign material introductionDNA/RNA fragmentationGenetic engineeringGuide RNA
The invention belongs to the field of gene engineering and particularly relates to a method for specifically knocking out a human CCR5 (Chemokine Receptor 5) gene by CRISPR (clustered regularly interspaced short palindromic repeat-associated)-Cas 9 and SgRNA (single guide RNA) for specifically targeting the CCR5 gene as well as an intermediate carrier and application thereof. The sgRNA for specifically targeting the human CCR5 gene, prepared by the method disclosed by the invention, can be used for accurately targeting the human CCR5 gene and realizing gene knockout. The preparation method is simple in steps and good in sgRNA targeting property; the knockout efficiency of a CRISPR-Cas 9 system is high.
Owner:AOMIAO BIOTECH GUANGZHOU CO LTD
Compositions and methods for the treatment of hemoglobinopathies
InactiveUS20150166969A1Improve the level ofAvoid the insertion of vector sequencesFusion with DNA-binding domainSugar derivativesThalassemiaGlobin genes
Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and / or homing endonuclease fusion protein(s) and / or CRISPR endonuclease(s) ad / or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human β-globin locus; (d) to disrupt a HbP silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbP silencing region; (e) to mutate one or more γ-globin gene promoter(s) to achieve increased expression of a γ-globin gene; (f) to mutate one or more δ-globin gene promoter(s) to achieve increased expression of a δ-globin gene; and / or (g) to correct one or more β-globin gene mutation(s).
Owner:NAT INST OF HEALTH DIRECTOR DEITR
Methods and compositions for the targeted modification of a genome
Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the LTVEC with a CRISPR / Cas system. Compositions and methods for generating a genetically modified non-human animal comprising one or more targeted genetic modifications in their germline are also provided.
Owner:REGENERON PHARM INC
Crispr-based genome modification and regulation
Owner:SIGMA ALDRICH CO LLC
Crispr/cas transcriptional modulation
ActiveUS20170204407A1Increased stability and activityMicrobiological testing/measurementVector-based foreign material introductionTranscriptional regulationBioinformatics
Owner:RGT UNIV OF CALIFORNIA
Methods and compositions for rna-guided treatment of HIV infection
A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.
Owner:TEMPLE UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com